A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

Similar documents
David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

Vernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida

Dermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Protocol applies to melanoma of cutaneous surfaces only.

Conflict of Interest 9/2/2014. Pathogenesis and Comparison of Atypical Spitz Nevi vs Benign Spitz, and Childhood Melanoma

Female 18. Deeply pigmented lesion on trunk.?warty naevus?seborrhoeic keratosis?malignant melanoma. The best diagnosis is:

There is NO single Melanoma Stain. > 6000 Mutations in Melanoma. What else can be done to discriminate atypical nevi from melanoma?

The Enigmatic Spitz Lesion

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy

Benign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more

Clinical characteristics

Pathology of the skin. 2nd Department of Pathology, Semmelweis University

Associate Clinical Professor of Dermatology MUSC

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

Management of Atypical Pigmented Lesions

Management of pediatric melanocytic lesions

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

Malignant tumors of melanocytes: Part 1. Deba P Sarma, MD., Omaha

Melanoma Update: 8th Edition of AJCC Staging System

Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018

Michael T. Tetzlaff MD, PhD

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

WHAT DOES THE PATHOLOGY REPORT MEAN?

Regression 2/3/18. Histologically regression is characterized: melanosis fibrosis combination of both. Distribution: partial or focal!

Ways to get into trouble, ideas on avoiding trouble, and diagnostic approaches to keep trouble at bay

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 12, :30 am 11:00 am

Melanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015

Michael T. Tetzlaff MD, PhD

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

The Pathology of Neoplasia Part II

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Melanocytic proliferations in sundamaged

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

المركب النموذج--- سبيتز وحمة = Type Spitz's Nevus, Compound SPITZ NEVUS 1 / 7

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

Impact of Prognostic Factors

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG

Multispectral Digital Skin Lesion Analysis. Summary

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda

Melanoma: The Basics. What is a melanocyte?

Epithelial Cancer- NMSC & Melanoma

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 13, :30 am 11:00 am

Histotechnological problems in dermatopathology and their possible consequences

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Melanoma Case Scenario 1

Mole mapping and monitoring. Dr Stephen Hayes. Associate Specialist in Dermatology, University Hospital Southampton

Case Report Micromelanomas: A Review of Melanomas 2mmand a Case Report

Melanoma Case Scenario 1

PHILIP E. LEBOIT. Histological Diagnosis of Nevi and Melanoma

BAP-oma & BEYOND MICHAEL A NOWAK, MD

Clinicopathologic Self- Assessment S003 AAD 2017

04/09/2018. Squamous Cell Neoplasia and Precursor Lesions. Agenda. Squamous Dysplasia. Squamo-proliferative lesions. Architectural features

Among the benign intraepithelial melanocytic proliferations, Inflamed Conjunctival Nevi. Histopathological Criteria. Resident Short Reviews

Histopathology of Melanoma

Page 1 of 3. We suggest the following changes:

Lentigo Maligna: Striking a Balance With the Risk-Benefit Ratio. Glen M. Bowen, MD Huntsman Cancer Institute University of Utah

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Neoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

21/07/2017. The «gray zone» of diagnosis is visible. Nevus Atypical nevus Melanoma. Melanoma ex-blue nevus

K Blessing, J J H Grant, D S A Sanders, M M Kennedy, A Husain, P Coburn

The Relevance of Cytologic Atypia in Cutaneous Neural Tumors

NAACCR Webinar Series 1

Melanoma 6/2/2011. Classification and Prognosis. Melanoma Statistics. American Cancer Society

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Corporate Medical Policy

Diagnoses of Cases 1. Lentigo, other melanosis and the acquired nevus 2. Variations on the acquired nevus 3. Dermal melanocytosis

Michael T. Tetzlaff MD, PhD

SKIN CANCER. Most common cancer diagnosis 40% of all cancers

Histopathology: skin pathology

Oncology and surgery. Dra. Irene Palacios. Clínica Universidad de Navarra

Specialist Referral Service Willows Information Sheets. Cancer in cats and dogs: Assessment of the patient

Simulators of melanoma

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Dr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology

MELANOMA. Some people are more likely to get a m Melanoma than others:

Transcription:

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

OBJECTIVES Discuss current trends and changing concepts in our understanding of atypical melanocytic proliferations. Suggest a practical approach to the management of atypical melanocytic lesions including Spitzoid melanocytic lesions and dysplastic nevi.

TRADITIONAL / SYMPLISTIC VIEW BENIGN MELANOMA

BENIGN NEVUS

MELANOMA

BENIGN OR MALIGNANT?

PROBLEMS WITH TRADITIONAL VIEWPOINT Unlike many other malignant neoplasms, the diagnosis of malignant melanoma is based on a constellation of many different features (any of which by themselves may be seen in benign lesions, some of which may not be seen in a given case). Even though indeterminate lesions do exist, because of medicolegal pressure many atypical cases are placed in the malignant category and are therefore overdiagnosed.

Implications of Overdiagnosis Cosmetic disfigurement Psychological implications Negative impact on insurance

Traditional view Regional lymph node metastasis is proof of malignancy! Problem: emerging data suggests that some atypical lesions (i.e atypical Spitz tumors in children) may show regional lymph node involvement without further progression.

BENIGN ATYPICAL MALIGNANT

BENIGN MELANOMA TRADITIONAL/ SYMPLISTIC VIEW BENIGN MELANOMA CONTEMPORARY/ PRACTICAL VIEW ATYPICAL/INTERMEDIATE

BENIGN No further treatment is necessary (given biopsy is representative) Increasing Atypia Or Uncertainty Excise if residual pigmentation remains Complete yet conservative re-excision with free microscopic margins MELANOMA In situ = 5mm Invasive = 1cm or greater +/- sentinel nodes *Note: Management should take into consideration other clinical risk factors (i.e family or personal history of melanoma, etc.)

MELANOCYTIC LESION BENIGN Clinical/ +/- ancillary studies/ expert consultation ATYPICAL MELANOMA Clinical/ +/- ancillarystudies/ expert consultation Morphologic simulator (i.e nevi of special site) No PROBABLY BENIGN WITH FEW ATYPICAL FEATURES (i.e low grade dysplastic nevi,?spitz nevi INDETERMINATE (i.e Atypical Spitz Nevi) BORDERLINE (i.e severely dysplastic Nevi)

Approach to Atypical Melanocytic Lesions: General Principles Diagnostic uncertainty should be expressed in the report and/or directly discussed with treating clinician. Treatment may be tailored to the differential diagnosis. If melanoma cannot be confidently ruled out (i.e borderline lesion), consider treating as melanoma of similar thickness (consider rendering a descriptive diagnosis, but report melanoma prognostic factors, i.e Breslow depth, mitotic activity, ulceration)

Practical Approach to Spitzoid Tumors

SPITZ NEVUS Melanocytic lesion with characteristic epithelioid morphology, First described by Sophie Spitz in 1948 as juvenile melanoma because of its propensity to occur in childhood, morphologically mimic melanoma but exhibit relatively indolent behaviour. 12 of 13 patients diagnosed as melanoma were alive following long term follow-up

SOPHIE SPITZ Differentiation histologically between the juvenile and adult melanomas could not be made with certainty in most cases.

There is no single feature that distinguishes a Spitz nevus from a melanoma

CYTOLOGIC ATYPIA Spitz Nevus Melanoma The individual cell that defines a Spitz nevus is by definition atypical

UPWARD PAGETOID SCATTER MELANOMA SPITZ NEVUS

MITOTIC ACTIVITY SPITZ NEVUS MELANOMA

SPITZOID MELANOCYTIC LESIONS SPITZ NEVUS/ TUMOR ATYPICAL SPITZ TUMOR SPITZOID MELANOMA

SPITZ NEVUS: Clinical features Great majority of lesions occur in childhood or in young adults Recent onset and rapid growth Usually less than 1 cm Pink-tan to reddish nodule Clinically symmetric with even borders

SPITZ NEVUS: Histology

SPITZ NEVUS

Rationale for Complete Excision of All Spitzoid Tumors Morphologic overlap with melanoma Recurrence of Spitz nevi may demonstrate features which may be very difficult to differentiate from melanoma Very rarely Spitz nevi with classic morphologic features have been known to metastasize.

SPITZ NEVUS CYTOLOGY AND ARCHITECTURE + APPROPRIATE CLINICAL SETTING SPITZ NEVUS + LESION COMPLETELY EXCISED

ATYPICAL SPITZ TUMOR Subset of Spitzoid neoplasms with clinically and pathologically disturbing features in which a melanoma cannot be excluded with absolute certainty. Lesions are more likely to behave more indolently, particularly in childhood, although regional lymph node involvement can occur. The significance of nodal deposits is unclear and does not necessarily indicate aggressive behavior (especially in children).

ATYPICAL SPITZOID TUMORS (cont.) Features with significant risk of nodal metastasis (esp. in children): Age greater than 10 years old Lesional diameter greater than 1 cm Ulceration Involvement of subcutaneous fat Mitotic activity of at least 6/mm 2

ATYPICAL SPITZ TUMOR: Histology

SPITZOID NEOPLASMS BENIGN INDETERMINATE MALIGNANT SPITZ NEVUS/TUMOR ATYPICAL SPITZ TUMOR SPITZOID MELANOMA TX: Excise TX: Excision +/- consider treating as melanoma Generally without systemic therapy TX: Wide excision +/- Sentinel node biopsy +/- Systemic therapy

Spitzoid melanomas are rare under the age of 20. The clinical diagnosis of a benign lesion in a child should be overruled only with very strong histologic evidence to the contrary. After age 50, a lesion with features resembling a Spitz nevus is more likely a melanoma than a nevus. In an older adult, a junctional Spitzoid tumor is most likely a melanoma. Beware of diagnosis of Spitz nevus on severely sun damaged skin (it is probably a melanoma).

How To Stay Out Of Court Spitz nevus is a high risk/low frequency diagnosis (like soft tissue or bone tumors. If pathologist does not see Spitz nevi on a regular basis and the patient is more than 20 years old, strongly consider sending to an expert. If Spitz nevi are seen on a regular basis but patient is more than 20 years old (unless typical diagnostic criteria are all present), strongly consider sending case to an expert. All Spitz nevi should be completely excised (although exceedingly rare, cases of classical Spitz nevi have been known to metastasize) Even experts disagree on Spitz tumors

CASE PRESENTATION

a) JUNCTIONAL MELANOCYTIC NEVUS b) MILDLY DYSPLASTIC JMN c) MALIGNANT MELANOMA d) PIGMENTED SUPERFICIAL BCC

a) Re-excise b) No further treatment necessary c) Additional clinical information necessary

Additional clinical information reveals that the biopsy was taken from a significantly larger clinical lesion. Re-excision recommended by pathologist ( reexcision should be considered, as clinically indicated, particularly if residual pigmentation remains ).

FINAL DIAGNOSIS Initial biopsy: Mildly dysplastic junctional melanocytic nevus, involving biopsy margins. Re-excision specimen: Malignant melanoma in-situ, superficial spreading type, arising in the background of dysplastic nevus..

SKIN MALIGNANT AREA BENIGN OR DYSPLASTIC AREA

Practical Approach to Dysplastic Nevi

Considerations prior to treatment Diagnostic pitfall (morphologic overlap with malignant melanoma) Association of dysplastic nevi and melanoma in the same lesion. dysplastic nevus melanoma Interobservor variability in diagnosis

Significance of Dysplastic Nevi Morphologic overlap with melanoma Marker of individuals at increased risk of developing melanoma Potential actual precursor of melanoma

Grading of Dysplastic Nevi BENIGN NEVUS DYSPLASTIC NEVUS MILD MODERATE SEVERE MELANOMA

Rationale For Grading of Dysplastic Nevi Separate slightly atypical but essentially benign nevi from those that: 1) might be confused with melanoma 2) possibly more likely to progress to melanoma 3) may be associated with a higher risk of melanoma

Practical Rationale for Grading of Dysplastic Nevi Conveys to the dermatologist Some information about the pathologist s concern about the lesion. The possible need for obtaining a second opinion. The decision to perform a complete excision or not (and possible extent of excision).

Problems With Grading of Dysplastic Nevi Not highly reproducible from one pathologist to another and therefore highly controversial. Some pathologists and dermatologists use the term dysplastic and atypical nevi interchangeably.

BENIGN NEVUS DYSPLASTIC NEVUS MILD MODERATE SEVERE MELANOMA Controversial: Clinicopathologic correlation Conservative re-excision Excise with at least 5mm margins

Lessons Learned from Medicolegal Cases. The diagnosis pertains only to the tissue submitted and assumes that the biopsy is representative. Claims involving dysplastic or atypical nevi appear to result in part from miscommunication between pathologist and dermatologist/clinician and most involve partial biopsies. Pathologist may use dysplastic or atypical nevus in a generic sense (i.e cytologically disturbing cells are present in lesion but lack diagnostic criteria for melanoma) and requests reexcision but the dermatologist may be reluctant to do so since to them these terms have a more specific meaning and connote a clinical syndrome or benign clinical entity.

NOTE: Optimal width of re-excision for atypical melanocytic lesions/indeterminate lesions are controversial, not based on hard data and are based largely on standard of care practices.

TAKE HOME MESSAGE! If there is disparity between the clinical and pathologic diagnosis, ask for a second read. Know your pathologist and his/her diagnostic tendencies in signing out melanocytic lesions.